Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOARGYS vs LARIN 1.5/30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute gouty arthritis,Dysmenorrhea,Management of acute pain
Prevention of pregnancy
100 mg orally twice daily.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment).
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Hepatic metabolism primarily via cytochrome P450 enzymes, including CYP2C9; formation of inactive metabolites, with less than 1% excreted unchanged in urine.
Ethinyl estradiol: primarily CYP3A4; norethindrone: primarily CYP3A4, with some reduction to active metabolites.
Primarily renal (70-80% unchanged; 10-15% as metabolites); biliary/fecal (5-10%).
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
85-90% (primarily albumin).
Ethinyl estradiol: 97-98% bound to albumin; Norethindrone: 93-99% bound to SHBG and albumin.
0.5-0.7 L/kg (indicates moderate tissue distribution).
Ethinyl estradiol: 2.5-5 L/kg; Norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Oral: 60-70% (first-pass metabolism).
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); Norethindrone ~50-60% (first-pass metabolism).
GFR 30-59 m L/min: 75 mg twice daily; GFR 15-29 m L/min: 50 mg twice daily; GFR <15 m L/min: not recommended.
No dose adjustment required in mild to moderate renal impairment (Cr Cl >=30 m L/min). Use contraindicated in severe renal impairment (Cr Cl <30 m L/min) or renal failure due to potential for fluid retention and hyperkalemia.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg twice daily; Child-Pugh C: not recommended.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, lowest possible effective dose should be used with close monitoring of liver function.
Not established; safety and efficacy not studied in patients <18 years.
Post-menarche adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). Safety and efficacy in pre-menarche girls have not been established.
No specific dose adjustment required; monitor renal function and adjust based on GFR.
Not indicated for postmenopausal women. No specific geriatric dose adjustments; however, consider increased risk of thromboembolic events and cardiovascular disease in women aged >40 years who smoke or have other risk factors.
Cardiovascular thrombotic events: NSAIDs, including LOARGYS, increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. The risk is higher in patients with cardiovascular disease or risk factors. LOARGYS is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cardiovascular thrombotic events,Gastrointestinal adverse events (bleeding, ulceration, perforation),Hypertension and exacerbation of hypertension,Renal effects: renal papillary necrosis, interstitial nephritis, and acute renal failure,Hepatic effects: elevations of liver enzymes, severe hepatic reactions,Anaphylactic reactions,Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis,Fluid retention and edema,Masking of inflammation and fever
Cardiovascular disease risk: smoking, hypertension, diabetes, hyperlipidemia,Thromboembolic events: increased risk in surgery, postpartum, or immobilization,Liver disease: discontinue if jaundice develops,Gallbladder disease: increased risk,Glucose intolerance: monitor in diabetics,Blood pressure elevation: monitor periodically,Depression: discontinue if severe
Hypersensitivity to LOARGYS or any component of the formulation,History of asthma, urticaria, or allergic-type reaction after taking aspirin or other NSAIDs,Patients with active gastrointestinal bleeding, peptic ulcer disease, or perforation,Advanced renal disease,Treatment of perioperative pain in the setting of CABG surgery,Patients with severe heart failure (NYHA Class IV)
Current or history of venous thromboembolism,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Known or suspected pregnancy,Liver tumors or active liver disease,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if taking with potassium-sparing diuretics or in renal impairment. Grapefruit juice may alter drug metabolism; limit intake.
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No specific dietary restrictions; can be taken with or without food.
FDA Pregnancy Category X. First trimester: high risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment.
First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters: Associated with adverse fetal outcomes including low birth weight, preterm delivery, and neonatal withdrawal symptoms. Avoid use during pregnancy due to known risks.
Contraindicated during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants.
Small amounts of ethinyl estradiol and norethindrone transfer into breast milk, with a milk-to-plasma ratio approximately 0.2-0.3 for norethindrone and <0.1 for ethinyl estradiol. May reduce milk production and composition. Use caution and consider alternative contraception in nursing mothers.
Avoid use during pregnancy due to teratogenicity; no dose adjustment guidelines exist as drug is contraindicated.
Contraindicated in pregnancy; no dose adjustment is applicable as the drug should be discontinued immediately upon confirmed pregnancy.
LOARGYS is an angiotensin II receptor blocker (ARB) indicated for hypertension. Avoid in pregnancy (Pregnancy Category D). Monitor serum potassium and renal function periodically. May cause dizziness; advise caution with driving. Combination with NSAIDs may reduce antihypertensive effect and increase renal risk.
Larin 1.5/30 is a monophasic combination oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for prevention of pregnancy and may also be used for management of acne and menstrual disorders. Advise patients to take at the same time daily to maintain consistent hormone levels. Counsel about breakthrough bleeding, especially during first cycles. Monitor for thrombotic events; use with caution in women with migraine with aura, hypertension, or smoking history over age 35. Effectiveness may be reduced with strong CYP3A4 inducers. Consider alternative contraception if patient is on chronic enzyme-inducing drugs. Use of NSAIDs can increase risk of breakthrough bleeding. Not recommended during breastfeeding or pregnancy.
Take exactly as prescribed, usually once daily.,Avoid salt substitutes containing potassium unless approved by doctor.,Do not stop taking without consulting your doctor.,Report symptoms like lightheadedness, fainting, or swelling.,Use effective contraception during treatment; not safe in pregnancy.
Take one tablet at the same time each day, with or without food.,If you miss a dose, follow the instructions in the package insert; use backup contraception if needed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Seek medical attention if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Do not smoke while taking this medication as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.,This medication does not protect against sexually transmitted infections; use condoms for STI prevention.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOARGYS vs LARIN 1.5/30, answered by our medical review team.
LOARGYS is a Combination Oral Contraceptive that works by LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.. LARIN 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOARGYS and LARIN 1.5/30 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOARGYS is: 100 mg orally twice daily.. The standard adult dose of LARIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOARGYS and LARIN 1.5/30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOARGYS is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: risk of fetal. LARIN 1.5/30 is classified as Category C. First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.